semaglutide compounding fda news Despite ruling, compounded GLP-1s are still giving Novo and Lilly headaches on the market fda semaglutide compounding news FDA
Description
Sara Klockars: Yes, yes, it does
PalmerDirectorHyman, Phelps & McNamara, P.C
As GLP-3 research advances, well better understand where it fits in the metabolic medicine toolbox and whether it offers meaningful advantages over or complements existing GLP-1 therapies
And we dont have long term data on these drugs
